<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801485</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-20190035-R</org_study_id>
    <nct_id>NCT04801485</nct_id>
  </id_info>
  <brief_title>Myo-inositol in Prevention of Gestational Diabetes Mellitus in China</brief_title>
  <official_title>Myo-inositol in Prevention of Gestational Diabetes Mellitus in High Risk Pregnant Women in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Women's Hospital School Of Medicine Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quzhou Maternal and Child Health Care Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Women's Hospital School Of Medicine Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myo-Inositol is a type of food additives, which plays an important role in insulin signal&#xD;
      pathway and is related to insulin sensitivity. Our randomized, double-centered,&#xD;
      placebo-controlled study is planned to recruit 360 pregnant women who is in high risk for&#xD;
      gestational diabetes. They will be assumed randomly 2 g of myo-inositol per day or placebo&#xD;
      from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th&#xD;
      gestational weeks. Perinatal outcomes about delivery time, neonatal weight will be&#xD;
      registered.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The random number table is compiled by the investigator who is specially responsible for grouping and saved. The investigator packaged and coded drugs according to random number table, and recorded. The packaged and numbered drugs are stored in the enrollment office.&#xD;
When the participants meet the inclusion criteria by care providers (doctors), the enrollment office generates a random number for each subject. The participants received the package of drugs according to their random number, and the random number was recorded in the record book.&#xD;
If there are adverse events or the subjects request to withdraw from the trial, the investigator should uncover the blind.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of gestational diabetes</measure>
    <time_frame>24-28th weeks gestation</time_frame>
    <description>The number of cases and incidence of gestational diabetes according to OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the perinatal outcomes-1</measure>
    <time_frame>Delivery</time_frame>
    <description>the incidence of macrosomia (macrosomia refers to a newborn weighs more than 4 kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the perinatal outcomes-2</measure>
    <time_frame>Delivery</time_frame>
    <description>weight gain during pregnancy (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the perinatal outcomes-3</measure>
    <time_frame>Delivery</time_frame>
    <description>the Caesarean-section incidence (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>Myo-inositol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol</intervention_name>
    <description>Active group receives myo-inositol 1 gram per day as well as health guidance about diet and exercise. From recruitment until OGTT.</description>
    <arm_group_label>Myo-inositol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (similar appearance but not containing myo-inositol) 1 gram per day before meals. Similar health guidance about diet and exercise. From recruitment until OGTT.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  During 12-16 weeks gestation&#xD;
&#xD;
          -  Meet any of the following: prepregnancy BMI &gt; 24, family history of diabetes (type 1&#xD;
             or 2), GDM history, history of delivering macrosomia, gestational history of&#xD;
             stillbirth;&#xD;
&#xD;
          -  Willing to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus diagnosed before pregnancy&#xD;
&#xD;
          -  Multiple gestation&#xD;
&#xD;
          -  Mental or cognitive impairment cannot complete the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danqing Chen, MD</last_name>
    <phone>86571-87061501</phone>
    <email>Chendq@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinning Chen, MD</last_name>
    <email>jhviolet@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xinning Chen</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinning Chen, M.D.</last_name>
      <email>jhviolet@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT04801485/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

